dual gip and glp-1 receptor agonist Science Behind GLP 1 Glucagon Agonists for Obesity Research | News & Announcements Machine learning designs new GCGR/GLP-1R
Description
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
[DOI] [PubMed] [Google Scholar] 88.Kawai T, et al
Tirzepatide follows a similar pattern, with indications spanning glycemic control and obesity treatment
To reduce these potential risks, healthcare providers are advised to closely monitor patients, particularly those with a history of gallbladder or biliary disease [49]
Recent studies have demonstrated abundant GLP-1 receptors in human retinal tissue, suggesting potential for direct neuroprotective effects [103]
